RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionShould read : Iovance Biotherapeutics' February 16, 2024 FDA TiLs therapy accelerated approval confirms ONCY's pelareorep TiLs advantage in the treatment of multiple solid tumors including pancreatic and breast cancer, without the need for an external intervention to achieve the TiL cells needed for an effective tumor killing approach.